Kisspeptin-10 vs MGF
A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
Kisspeptin-10
Kisspeptin-10 is the biologically active 10-amino acid C-terminal fragment of kisspeptin, a neuropeptide that acts as the master regulator of the hypothalamic-pituitary-gonadal (HPG) axis. By activating KISS1R (GPR54) in the hypothalamus, it triggers pulsatile GnRH release, which drives LH, FSH, and downstream testosterone and estrogen production. It is the upstream signal that 'turns on' the reproductive axis — with research applications spanning fertility, hypogonadism, post-cycle therapy support, and age-related hormonal decline.
Full profileMGF
MGF (Mechano Growth Factor) is a splice variant of IGF-1 produced locally in muscle tissue in response to mechanical loading (exercise, especially eccentric loading). Unlike circulating IGF-1 which is produced primarily by the liver, MGF is generated within the muscle itself and acts locally to activate satellite cells (muscle stem cells) — the cells responsible for muscle repair, growth, and adaptation. It is considered the primary local anabolic signal generated by resistance training.
Full profile| Kisspeptin-10 | MGF | |
|---|---|---|
| Category | Performance & Growth Hormone | Performance & Growth Hormone |
| Also known as | KP-10, Metastin(112-121), KISS1R agonist | Mechano Growth Factor, IGF-1Ec, Insulin-like Growth Factor splice variant |
| Evidence | FDA-approved | Preclinical only |
| Dosing range | 50mcg–250mcg mcg, 1–2x daily (pulsatile administration is important — avoid continuous infusion) | 100mcg–300mcg mcg, Post-workout (within 30–60 minutes of training), 3–4x weekly |
| Administration | Subcutaneous injection, Intranasal, Intravenous (clinical studies — produces most reliable LH pulses) | Intramuscular injection (into worked muscle — critical for local effect), Subcutaneous injection (produces more systemic distribution) |
| Key side effects | Generally well-tolerated in clinical trials, Nausea (mild, uncommon), Potential for over-stimulation of the HPG axis at high doses (rarely significant), Theoretical desensitization with continuous (non-pulsatile) dosing | Localized muscle swelling at injection site (normal response), Hypoglycemia (less pronounced than IGF-1 DES but present), Very short half-life means side effects are brief, Potential overuse injury if post-workout injection is used consistently without adequate recovery |
| Cited sources | 3 references | 3 references |
Key differences
- Evidence level differs: Kisspeptin-10 is fda-approved, while MGF is preclinical only.
- Administration: Kisspeptin-10 — Subcutaneous injection, Intranasal, Intravenous (clinical studies — produces most reliable LH pulses); MGF — Intramuscular injection (into worked muscle — critical for local effect), Subcutaneous injection (produces more systemic distribution).
- Frequency: Kisspeptin-10 is typically 1–2x daily (pulsatile administration is important — avoid continuous infusion); MGF is Post-workout (within 30–60 minutes of training), 3–4x weekly.
How each works
Kisspeptin-10
Kisspeptin neurons in the arcuate nucleus form the pulse generator for GnRH secretion — without kisspeptin signaling, reproductive function ceases. Human clinical trials confirm that IV kisspeptin-10 produces rapid, dose-dependent LH pulses in both males and females, restoring hormonal function in hypogonadotropic hypogonadism. Kisspeptin-54 (the longer form) has been studied in human fertility treatments with successful outcomes. Unlike direct LH/FSH administration, kisspeptin works upstream at the hypothalamus, preserving the natural pulsatile release pattern and avoiding receptor desensitization associated with continuous GnRH agonists.
MGF
MGF is encoded by the IGF-1 gene but produced via alternative splicing that generates a unique 49-amino acid C-terminal E-peptide (Ec peptide). The Ec peptide has distinct biological activity from the IGF-1 domain — it directly activates satellite cell proliferation through a receptor pathway separate from the standard IGF-1R. Studies in rodents show that local MGF injection produces significant muscle hypertrophy in the injected limb without systemic IGF-1 elevation. MGF expression spikes within 30 minutes of resistance exercise and declines over 24–48 hours — aligning precisely with the post-exercise anabolic window.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.